You are here: Industry Insights > RLF-100

News List

NeuroRx and Relief Therapeutics announce enrollment of 150 patients in phase 2b/3 trial of RLF-100™ for Critical COVID-19 with Respiratory Failure prnewswire
November 16, 2020
NeuroRx, Inc. and Relief Therapeutics Holdings AG announced that as of today, 150 patients (out of a targeted enrollment of 165) have been enrolled in the ongoing phase 2b/3 trial of RLF-100™ (aviptadil) for treating respiratory failure in patients with..
NeuroRx, Relief Releases RLF-100 Data for COVID-19 Respiratory Failure americanpharmaceuticalreview
October 19, 2020
Relief Therapeutics and NeuroRx has announced topline results from 45 patients assessed in an open-label prospective study where 21 patients admitted to an intensive care unit (ICU) with critical COVID-19 and respiratory failure were treated with ...
NeuroRx Submits EUA Request for RLF-100 for COVID-19, Respiratory Failure americanpharmaceuticalreview
September 30, 2020
NeuroRx has submitted a request for an Emergency Use Authorization (EUA) with the FDA for the use of RLF-100™ aviptadil in patients who are receiving intensive care and who have exhausted all approved treatments.
EUA requested for potential COVID-19 respiratory failure treatment europeanpharmaceuticalreview
September 27, 2020
An Emergency Use Authorization (EUA) request for the use of RLF-100™ (aviptadil) in critical COVID-19 patients was submitted to the US FDA.
FDA Grants Inhaled Use IND for RLF-100 for COVID-19 to Prevent Respiratory Failure americanpharmaceuticalreview
August 12, 2020
NeuroRx and Relief Therapeutics announced NeuroRx has been granted Investigational New Drug (IND) permission to test RLF-100 (aviptadil) for inhaled use in patients with moderate and severe COVID-19 in order to prevent progression to respiratory failure.
RLF-100 Trial Shows Rapid Recovery from COVID-19 Respiratory Failure americanpharmaceuticalreview
August 10, 2020
NeuroRx and Relief Therapeutics announced that RLF-100 (aviptadil) showed rapid recovery from respiratory failure in the most critically ill patients with COVID-19.
RLF-100 shown to deliver rapid recovery from respiratory failure in Covid-19 patients pharmaceutical-business-review
August 07, 2020
NeuroRx and Relief Therapeutics said that RLF-100 (aviptadil) delivered quick recovery from respiratory failure in the most critically ill patients suffering from Covid-19 in a phase 2/3 clinical trial.
NeuroRx, Relief Announce Fast Track Designation for Respiratory Distress Treatment in COVID-19 americanpharmaceuticalreview
July 03, 2020
NeuroRx, in partnership with Relief Therapeutics, announced the U.S. Food and Drug Administration (FDA) awarded Fast Track Designation to NeuroRx for the investigation of RLF-100 (Aviptadil) for the treatment of acute lung injury ...
FDA grants fast track status to NeuroRx’s Covid-19 drug candidate pharmaceutical-technology
June 28, 2020
The US Food and Drug Administration (FDA) has granted fast track designation to RLF-100 (Aviptadil), which is being developed by NeuroRx and Relief Therapeutics to treat acute lung injury / acute respiratory distress syndrome caused by Covid-19.
Relief Therapeutics, NeuroRx Expand Clinical Trial of RLF-100 americanpharmaceuticalreview
June 16, 2020
Relief Therapeutics and its U.S. partner, NeuroRx, announced the Phase 2/3 clinical trial evaluating RLF-100 as a treatment for critical COVID-19 with respiratory failure has been expanded to include patients receiving high flow oxygen and ...

Previous page 1 2 Next page